Clinical trials: Aggressive Behaviour
Level of Digital Game Addiction, Level of Cyberbullying
Digital Game Addiction and Cyberbullying in Adolescents
With the widespread use of technology and internet, digital game addiction and cyberbullying behaviors have increased among adolescents. Effective interventions are needed to prevent these behaviors.
- Trial name
- NCT06241989
- Testing
- health education supported by motivational interviewing
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Gazi University
Coronary Artery Disease, Atherosclerosis
Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)
The purpose of this study is to evaluate the role of coronary CT angiogram (CCTA) as a superior guide for the assessment of coronary artery plaque and guiding treatment decisions.
- Conditions
- Coronary Artery Disease, Atherosclerosis, Heart Attack
- Trial name
- ARTCAP (NCT06280976)
- Testing
- Statin, Aspirin tablet, Nexlizet
- Where
- United States
- Sponsor
- University of Louisville
Lymphoma, Extranodal NK-T-Cell
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma
This study is to explore the efficacy and safety of GLIDE regiment in patients with aggressive NK/T cell lymphoma.
- Trial name
- NCT03154918
- Testing
- GLIDE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sichuan University
Neuroendocrine Tumors, Gastro Entero Pancreatic Neuroendocrine Tumors
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
The aim of this phase I-II study is to evaluate the efficacy and toxicity of PRRT with 177Lu-DOTATATE (Lu-PRRT) associated to metronomic chemotherapy with Capecitabine in patients affected by aggressive FDG-positive…
- Trial name
- LuX (NCT02736500)
- Testing
- 28 GBq 177Lu-DOTATATE, 22 GBq 177Lu-DOTATATE
- Where
- 2 sites in Italy
- Volunteers
- 39 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Lymphoma, HIV
Autologous Transplant in HIV Patients (BMT CTN 0803)
This study is a Phase II, multicenter trial assessing overall survival after autologous hematopoietic stem cell transplantation using a BEAM transplant regimen (carmustine, etoposide, cytarabine, melphalan) in lymphoma patients…
- Trial name
- NCT01141712
- Testing
- Autologous transplant, BCNU, Etoposide
- Where
- 16 sites in United States
- Volunteers
- 43 people
- Sponsor
- Medical College of Wisconsin
Lymphoma
Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00052936
- Testing
- filgrastim, rituximab, CHOP regimen
- Where
- 174 sites in Germany, Switzerland
- Volunteers
- 1,506 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
EBV Related Non-Hodgkin's Lymphoma, Primary CNS Lymphoma
Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL Patients with relapsed refractory subtypes of DLBCL who…
- Conditions
- EBV Related Non-Hodgkin's Lymphoma, Primary CNS Lymphoma, Primary Testicular Lymphoma
- Trial name
- DuRIANS (NCT03212807)
- Testing
- Durvalumab, Lenalidomide
- Where
- 4 sites in Singapore
- Sponsor
- Singapore General Hospital
Peripheral T-cell Lymphomas
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
The primary objectives of this study are to: 1. establish the safety and dose limiting toxicities of combining alemtuzumab with CHOP chemotherapy for patients with newly diagnosed aggressive T-cell lymphomas; and 2.
- Trial name
- ACCAPELA (NCT00453427)
- Testing
- Alemtuzumab (Campath-1H)
- Where
- 5 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Aggressive Behavior
Individual and Group Intervention Formats With Aggressive Children
The planned study will randomly assign aggressive children to one of two versions of the Coping Power child component. The two versions of Coping Power will either deliver the child component of the program in the usual small…
- Trial name
- NCT01710969
- Testing
- Individual intervention, Group Intervention
- Volunteers
- 360 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Lymphoma
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00101010
- Testing
- Filgrastim, Pegfilgrastim, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Hodgkin's Lymphoma - Relapsed/Refractory, Non-Hodgkin's Lymphoma - Aggressive
GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma
Objective of study: To evaluate the safety and efficacy of infusional gemcitabine prior to HDM (high-dose melphalan) as HDCT (High Dose Chemotherapy) followed by autologous stem cell transplantation in patients with…
- Conditions
- Hodgkin's Lymphoma - Relapsed/Refractory, Non-Hodgkin's Lymphoma - Aggressive, Follicular Lymphoma
- Trial name
- GEMHDM2014 (NCT02295722)
- Testing
- Gemcitabine, Melphalan, ASCT
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- AHS Cancer Control Alberta
Malignant Lymphoma, Relapsed Non Hodgkin Lymphoma
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
In the study, we aimed to characterize the role of FDG PET/CT surveillance at 12 months of malignant lymphoma in asymptomatic patients after a first complete remission and to define a rational follow-up strategy.
- Conditions
- Malignant Lymphoma, Relapsed Non Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Diagnostic Imaging
- Trial name
- LYMPHOTEP1 (NCT04464590)
- Volunteers
- 100 people
- Sponsor
- University Hospital, Brest
Generalized Aggressive Periodontitis, Aggressive Periodontitis
Alternative Antibiotic Regime in the Treatment of GAgP
The objective of this randomized clinical study was to evaluate the effect of systemic administration of moxifloxacin compared to amoxicillin plus metronidazole combined with non-surgical treatment in patients with generalized…
- Trial name
- NCT02223702
- Testing
- Amoxicillin, Metronidazole, Moxifloxacin
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Kocaeli University
Prostate Cancer, Obesity
Exercise, Prostate Cancer and Circulating Tumour Cells
Obesity, known to be associated with a pro-inflammatory, pro-thrombotic humoral milieu, confers a worse prognosis in prostate cancer (PrCa). Circulating tumour cells (CTCs) are identified in the blood in advanced cancer.
- Trial name
- ExPeCT (NCT02453139)
- Testing
- Exercise
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 67 people
- Sponsor
- University of Dublin, Trinity College
Bullying and Victimization
The Effect of Awareness Training on Peer Bullying
This study examined the effect of awareness training on peer bullying, victimization, empathy, and sympathy levels in adolescents. A total of 64 students were randomly assigned to an intervention group or control group.
- Trial name
- NCT07383545
- Testing
- Awareness training on peer bullying
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Selcuk University
Chronic Periodontitis, Aggressive Periodontitis
Effect of Surgical Therapy on RANKL/OPG (Osteoprotegerin) System
In the present clinical study including chronic, aggressive periodontitis and healthy individuals, the investigators aimed to determine the RANKL, osteoprotegrin (OPG), Interleukin-1 (IL-1β), IL-10, IL-1β levels in gingival…
- Conditions
- Chronic Periodontitis, Aggressive Periodontitis, RANKL/OPG Ratio, Gingival Crevicular Fluid
- Trial name
- NCT02190773
- Where
- Turkey (Türkiye)
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Refractory Aggressive Non-Hodgkin's Lymphoma, Relapsing Aggressive Non-Hodgkin's Lymphoma
Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas
Study Proposal: Other drugs where synergy with Gemcitabine has been observed are Cisplatinum, Taxol, Taxotere, Etoposide and alkylating agents.
- Trial name
- NCT01538641
- Testing
- Rituximab, Gemcitabine, Oxaliplatin
- Volunteers
- 43 people
- Sponsor
- Auxilio Mutuo Cancer Center
Aggression
NIH R01 Friend to Friend With Coaching
This study examines the effectiveness of the Friend to Friend (F2F) program when conducted by teachers and counselors with active coaching from the research team.
- Trial name
- NCT04164472
- Testing
- Friend to Friend (F2F) with Coaching
- Where
- United States
- Volunteers
- 5,250 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Intellectual Disability, Developmental Disability
Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
Innovative treatments are urgently needed for severe behavioural problems (SBPs) in adults with intellectual and developmental disabilities (IDD).
- Conditions
- Intellectual Disability, Developmental Disability, Aggression, Behavior Problem
- Trial name
- N-AND (NCT05273320)
- Testing
- Nabilone
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Hsiang-Yuan Lin
Mental Health, Aggressive Childhood Behavior
Mental Health Prevention Among Preschool Children Using a Culturally Adapted Version of ICPS
Mental health in Chilean children and families is an urgent public health problem. Prevalence of psychiatric disorders among children between 4 and 11 years old is 27.8%, a higher percentage than was found in adolescents between…
- Conditions
- Mental Health, Aggressive Childhood Behavior, Problem Behavior, Social Behavior
- Trial name
- NCT03383172
- Testing
- I Can Problem Solve (ICPS) Program
- Where
- Chile
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Fundación San Carlos de Maipo